Enliven Therapeutics SEC filings document a clinical-stage biopharmaceutical issuer developing small-molecule therapeutics, with disclosures centered on ELVN-001 for chronic myeloid leukemia and related operating results and cash resources. Current reports furnish quarterly and annual financial results and attach business updates describing ENABLE clinical-trial activity, regulatory-development topics, and program plans.
Proxy and governance filings describe annual meeting matters, board composition, committee leadership, executive transitions, director compensation, equity awards, and stockholder voting procedures. The filings also identify Enliven common stock on the Nasdaq Global Select Market and record material-event amendments when furnished press-release exhibits are corrected.
Enliven Therapeutics ownership filing: A group including Polar Capital Holdings Plc, Polar Capital LLP and Polar Capital Funds PLC - Biotechnology Fund reports beneficial ownership of 5,056,807 shares of Enliven Therapeutics common stock. The filing states this equals 8.46% of the class, based on 60,904,946 shares outstanding as of May 7, 2026.
The filing is a joint Schedule 13G/A amendment signed by Nicholas Farren as Chief Operating Officer for the reporting entities and affirms sole voting and sole dispositive power over the reported shares.
Enliven Therapeutics, Inc. reports that Vestal Point Capital and Ryan Wilder beneficially own 3,250,000 shares of Common Stock, representing 5.4% of the class. The percentage is calculated using 59,800,406 shares outstanding as of February 19, 2026, per the company's referenced annual report. The filing states the shares are held by the Vestal Point Fund and Account and that the Reporting Persons have shared voting and dispositive power over these shares. The amendment is signed by Ryan Wilder on 05/15/2026.
Venrock-related reporting persons disclosed beneficial ownership of 1,726,331 shares of Enliven Therapeutics common stock as of March 31, 2026. The filing lists shared voting and dispositive power over those shares rather than sole control.
The ownership breaks down as 376,873 shares held by Venrock Healthcare Capital Partners III, 37,695 shares by VHCP Co-Investment Holdings III, and 1,311,763 shares by Venrock Healthcare Capital Partners EG. The filing uses 60,889,655 shares outstanding as of March 31, 2026 as the denominator, producing a reported 2.8% ownership figure for each listed reporting person.
Fairmount Funds Management LLC and related reporting persons amended a Schedule 13G to report beneficial ownership of 1,855,644 shares of Enliven Therapeutics, Inc. common stock, representing 3.1% based on 59,800,406 shares outstanding as of February 19, 2026 per the issuer's Form 10-K. The filing states that Fund II delegated sole voting and dispositive power to Fairmount and includes disclaimers of beneficial ownership under Section 13(d).
Enliven Therapeutics ownership update: Commodore Capital and related filers report beneficial ownership of 4,800,940 shares of common stock as of March 31, 2026. The position comprises 3,275,000 issued shares and 1,525,940 shares issuable upon exercise of a pre-funded warrant, subject to a 9.99% Beneficial Ownership Limitation.
Ownership calculations use 60,889,655 shares outstanding as of March 31, 2026 (reported in the Form 10-Q filed May 7, 2026), yielding an indicated 7.7% stake.
Polar Capital group reports holding 5,065,933 shares (Common Stock) of ENLIVEN THERAPEUTICS, INC. The filing amends a prior Schedule 13G and states this equals 8.47% of the class based on 60,904,946 shares outstanding as of May 7, 2026.
The disclosure lists Polar Capital Holdings Plc, Polar Capital LLP and Polar Capital Funds PLC - Biotechnology Fund as joint filers, with sole voting and dispositive power over the reported shares. The amendment is signed by Nicholas Farren, Chief Operating Officer, on behalf of the reporting entities.
Enliven Therapeutics reported a net loss of $23.6M, or $0.38 per share, for the three months ended March 31, 2026, compared with a $28.5M loss a year earlier. Research and development spending declined to $20.7M, while general and administrative expenses were $7.1M. The company ended the quarter with $452.4M in cash, cash equivalents and marketable securities, which management believes will fund operations for at least 12 months. Enliven is prioritizing its BCR-ABL program, advancing ELVN-001 toward a pivotal trial, and is exploring strategic alternatives for ELVN-002 and has decided not to develop its HER2 program beyond 2025.
Enliven Therapeutics reported first quarter 2026 results, highlighting progress on its chronic myeloid leukemia candidate ELVN-001 and a strong cash position. ELVN-001 showed positive initial Phase 1b data, with additional Phase 1 results expected mid-2026 and initiation of the Phase 3 ENABLE-2 pivotal trial planned for the second half of 2026.
For the quarter ended March 31, 2026, Enliven posted a net loss of $23.6 million, improving from $28.5 million a year earlier. Research and development expenses were $20.7 million versus $24.9 million, while general and administrative costs were $7.1 million versus $6.8 million. Cash, cash equivalents and marketable securities totaled $452.4 million, expected to fund operations into the first half of 2029.
Enliven Therapeutics director Joseph Lyssikatos reported proposed sales of common stock under a Form 144 notice. The filing lists 25,000 shares associated with Jefferies as the broker and multiple past dispositions totaling 130,000 shares across February–March 2026 with aggregate proceeds shown per trade. The filing documents routine resale activity by an insider; timing and additional proceeds treatment are shown by the listed trade dates.